Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Short-term Investments: 2017-2025

Historic Short-term Investments for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $346.6 million.

  • Dianthus Therapeutics' Short-term Investments rose 40.08% to $346.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.6 million, marking a year-over-year increase of 40.08%. This contributed to the annual value of $252.4 million for FY2024, which is 509.88% up from last year.
  • Dianthus Therapeutics' Short-term Investments amounted to $346.6 million in Q3 2025, which was up 41.97% from $244.2 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Short-term Investments peaked at $346.6 million during Q3 2025, and registered a low of $15.0 million during Q2 2023.
  • In the last 3 years, Dianthus Therapeutics' Short-term Investments had a median value of $47.3 million in 2024 and averaged $141.5 million.
  • As far as peak fluctuations go, Dianthus Therapeutics' Short-term Investments crashed by 82.32% in 2023, and later surged by 659.33% in 2024.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Short-term Investments stood at $60.1 million in 2022, then crashed by 31.16% to $41.4 million in 2023, then surged by 509.88% to $252.4 million in 2024, then soared by 40.08% to $346.6 million in 2025.
  • Its Short-term Investments stands at $346.6 million for Q3 2025, versus $244.2 million for Q2 2025 and $253.1 million for Q1 2025.